January 1983 in “Side effects of drugs annual” Beta-blockers and anti-anginal medications have various side effects and interactions that require careful monitoring and individualized treatment.
13 citations
,
July 2004 in “Skinmed” Common types of non-scarring hair loss have various causes and treatments, but more effective solutions are needed.
September 2016 in “Princeton University Press eBooks” The document concludes that understanding health requires considering evolutionary perspectives on reproductive fitness, and recognizing the complexity of factors like diet, testosterone, and sexual orientation.
April 2026 in “Frontiers in Medicine” Farudodstat may help prevent hair loss in alopecia areata by stopping immune attacks on hair follicles.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.
June 2024 in “Indian Dermatology Online Journal” Topical tofacitinib is effective and safe for treating alopecia areata.
1 citations
,
March 2025 in “Pediatric Dermatology” Alopecia areata causes round patches of hair loss, especially in children.
7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
4 citations
,
March 2025 in “The Journal of Dermatology” Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
4 citations
,
July 2024 in “Pharmacology Research & Perspectives” Ritlecitinib is safe and may effectively treat alopecia areata.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Abatacept may help some people with alopecia areata regrow hair.
January 2026 in “Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
November 2025 in “Journal of Investigative Dermatology” IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.
June 2025 in “British Journal of Dermatology” Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
December 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair significantly.
October 2024 in “Clinical Cosmetic and Investigational Dermatology” Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
December 2024 in “Clinical Cosmetic and Investigational Dermatology” Vitiligo often starts young, is linked to family history and stress, and requires comprehensive care including psychological support.
Higher PD-1 levels mean fewer CD8+ T cells in alopecia areata hair follicles.
18 citations
,
June 2010 in “Cell Stress and Chaperones” Heat treatment increases hair loss in certain mice.
October 2025 in “Dermatologica Sinica” A personalized treatment combining traditional and new therapies may improve hair loss outcomes in alopecia areata.
May 2026 in “Indian Journal of Dermatology” Rituximab effectively managed a difficult case of juvenile lupus with complications, reducing the need for steroids.
May 2021 in “Journal of the Endocrine Society” Hashimoto's can rarely change to Graves disease, needing careful monitoring.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.
21 citations
,
April 2025 in “MedComm” Alopecia areata causes unpredictable hair loss, and more research is needed to fully understand and treat it effectively.
18 citations
,
June 2017 in “Oncotarget” Digoxin is linked to a higher risk of anemia in patients with atrial fibrillation and heart failure.
May 2026 in “Mayo Clinic Proceedings” Early diagnosis and coordinated care are crucial for managing lupus effectively.
September 2025 in “JID Innovations” Squaric acid dibutylester promotes hair growth by activating immune cells, especially macrophages.
August 2025 in “Dermatology and Therapy” JAK inhibitors show promise for treating alopecia areata but have serious side effects.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.